OFI Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

OFI Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	$190K	Buy	1,212 +53	+5%	+$9.67K	0.01%	1228
2015 Q2	$210K	Buy	1,159 +109	+10%	+$18.8K	0.01%	1226
2015 Q1	$182K	Sell	1,050 -111	-10%	-$20.1K	0.01%	1287
2014 Q4	$215K	Buy	1,161 +232	+25%	+$43K	0.01%	1171
2014 Q3	$154K	Buy	929 +74	+9%	+$12.2K	0.01%	1284
2014 Q2	$134K	Buy	855 +227	+36%	+$35.8K	0.01%	1349
2014 Q1	$96K	Sell	628 -156	-20%	-$24.8K	0.01%	1438
2013 Q4	$104K	Buy	784 +58	+8%	+$6.96K	0.01%	1398
2013 Q3	$84K	Sell	726 -116	-14%	-$12.7K	0.01%	1400
2013 Q2	$78K	Buy	+842	New	+$81.1K	0.01%	1372

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

OFI Advisors's ALXN Position: Q3 2015 in Review

OFI Advisors increased its Alexion Pharmaceuticals (ALXN) stake by 4.6% in Q3 2015, buying an estimated $9.67K and bringing the position to 1,212 shares worth $190K. The position accounts for 0.01% of the portfolio, ranked #1228.

OFI Advisors first reported a position in ALXN in Q2 2013 and has held it in 10 quarters since. The position peaked at $215K in Q4 2014. 515 funds tracked by Wall St. Rank hold ALXN as of Q3 2015.

OFI Advisors held 1,212 shares of Alexion Pharmaceuticals worth $190K as of Q3 2015.
OFI Advisors bought 53 Alexion Pharmaceuticals shares in Q3 2015, an estimated $9.67K.
Alexion Pharmaceuticals made up 0.01% of OFI Advisors's portfolio in Q3 2015, its #1228 holding.
OFI Advisors first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 10 quarters since.
OFI Advisors's Alexion Pharmaceuticals position peaked at $215K in Q4 2014.
515 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2015.

Based on OFI Advisors's 13F filing for Q3 2015, filed 13 Nov 2015.